News Pfizer fears rough ride with NICE over breast cancer drug Concerns over NICE's treatment of add-on therapies.
News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
